A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy

Journal of the Peripheral Nervous System

Volumn 18, Issue 4, 2013, Pages 321-330

  Hahn, Angelika F ^a   Beydoun, Said R ^b   Lawson, Victoria ^c   Oh, Myungshin ^d   Empson, Victoria G ^e   Leibl, Heinz ^e   Ngo, Leock Y ^d   Gelmont, David ^d   Koski, Carol L ^f  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d BAXTER HEALTHCARE CORPORATION   (United States)

^e BAXTER INNOVATIONS GMBH   (Austria)

^f not available   (United States)

Author keywords

intravenous immunoglobulin; multifocal motor neuropathy; randomized placebo controlled trial

Indexed keywords

IMMUNOGLOBULIN; PLACEBO; IMMUNOLOGIC FACTOR;

ADULT; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GRIP STRENGTH; HEADACHE; HUMAN; LUNG EMBOLISM; MALE; MOTOR NEUROPATHY; MUSCLE STRENGTH; NAUSEA; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; VISUAL ANALOG SCALE; AGED; CLINICAL TRIAL; COMPLICATION; DISABILITY; DOUBLE BLIND PROCEDURE; MIDDLE AGED; MOVEMENT DISORDERS; MULTICENTER STUDY; PAIN MEASUREMENT; POLYNEUROPATHIES; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; CROSS-OVER STUDIES; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; MOVEMENT DISORDERS; PAIN MEASUREMENT; POLYNEUROPATHIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84890521219     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/jns5.12046     Document Type: Review

References (28)

1. 1 antibodies: a double-blind, placebo-controlled study. Neurology 44: 429-432.
2. Ballow M, (2007). Safety of IVIG therapy and infusion-related adverse events. Immunol Res 38: 122-132. (Pubitemid 47574903)
3. Caress JB, Hobson-Webb L, Passmore LV, Finkbiner AP, Cartwright MS, (2009). Case-control study of thromboembolic events associated with IV immunoglobulin. J Neurol 256: 339-342.
4. Carpo M, Cappellari A, Mora G, Pedotti R, Barbieri S, Scarlato G, Nobile-Orazio E, (1998). Deterioration of multifocal motor neuropathy after plasma exchange. Neurology 50: 1480-1482. (Pubitemid 28240378)
5. Cats EA, Jacobs BC, Yuki N, Tio-Gillen AP, Piepers S, Franssen H, van Asseldonk JT, van den Berg LH, van der Pol WL, (2010a). Multifocal motor neuropathy: association of anti-GM1 IgM antibodies with clinical features. Neurology 75: 1961-1967.
6. Cats EA, Van der Pol WL, Piepers S, Franssen H, Jacobs BC, van den Berg-Vos RM, Kuks JB, van Doorn PA, van Engelen BG, Verschuuren JJ, Wokke JH, Veldink JH, van den Berg LH, (2010b). Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology 75: 818-825.
7. Donaghy M, Mills KR, Boniface SJ, Simmons J, Wright I, Gregson N, Jacobs J, (1994). Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry 57: 778-783. (Pubitemid 24214955)
8. Eftimov F, van Schaik IN, (2011). Immunotherapy of multifocal motor neuropathy. Expert Opin Biol Ther 11: 329-342.
9. Federico P, Zochodne DW, Hahn AF, Brown WF, Feasby TE, (2000). Multifocal motor neuropathy improved by IVIg. Randomized, double-blind, placebo-controlled study. Neurology 55: 1256-1262.
10. Galban-Horcajo F, Fitzpatrick AM, Hutton AJ, Dunn SM, Kalna G, Brennan KM, Rinaldi S, Yu RK, Goodyear CS, Willison HJ, (2013). Antibodies to heteromeric glycolipid complexes in multifocal motor neuropathy. Eur J Neurol 20: 62-70.
11. Gelfand EW, (2006). Differences between IVIG products: impact on clinical outcome. Int Immunopharmacol 6: 592-599.
12. Joint Task Force of the EFNS and the PNS (2010). European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. J Peripher Nerv Syst 15: 295-301.
13. Léger J-M, Chassande B, Musset L, Meininger V, Bouche P, Baumann N, (2001). Intravenous immunoglobulin therapy in multifocal motor neuropathy. A double-blind, placebo-controlled study. Brain 124: 145-153. (Pubitemid 32055996)
14. Merkies IS, Schmitz PI, van der Meche FG, Samijn JP, van Doorn PA, (2002). Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 72: 596-601. (Pubitemid 34462813)
15. Meuth SG, Kleinschnitz C, (2010). Multifocal motor neuropathy: update on clinical characteristics, pathophysiological concepts and therapeutic options. Eur Neurol 63: 193-204.
16. Olney RK, Lewis RA, Putnam TD, Campellone JV Jr, American Association of Electrodiagnostic Medicine (2003). Consensus criteria for the diagnosis of multifocal motor neuropathy. Muscle Nerve 27: 117-121. (Pubitemid 36083455)
17. Rajabally YA, Kearney DA, (2011). Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: a two-year study. J Neurol Sci 308: 124-127.
18. Sharrack B, Hughes RA, (1999). The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis. Mult Scler 5: 223-233. (Pubitemid 29405617)
19. Stangel M, Kiefer R, Pette M, Smolka MN, Marx P, Gold R, (2003). Side effects of intravenous immunoglobulins in neurological autoimmune disorders: a prospective study. J Neurol 250: 818-821. (Pubitemid 36898113)
20. Umapathi T, Hughes RA, Nobile-Orazio E, Léger JM, (2009). Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Database Syst Rev 3: CD003217.
21. van Asseldonk JT, Franssen H, van den Berg-Vos RM, Wokke JH, van den Berg LH, (2005). Multifocal motor neuropathy. Lancet Neurol 4: 309-319. (Pubitemid 40545042)
22. van Asseldonk JT, van den Berg LH, Kalmijn S, van den Berg-Vos RM, Polman CH, Wokke JH, Franssen H, (2006). Axon loss is an important determinant of weakness in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 77: 743-747. (Pubitemid 43837201)
23. Van den Berg LH, Kerkhoff H, Oey PL, Franssen H, Mollee I, Vermeulen M, Jennekens FGI, Wokke JHJ, (1995). Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 59: 248-252.
24. Van Schaik IN, Bossuyt PMM, Brand A, Vermeulen M, (1995). Diagnostic value of GM1 antibodies in motor neuron disorders and neuropathies: a meta-analysis. Neurology 45: 1570-1577.
25. Van Schaik IN, van den Berg LH, de Haan R, Vermeulen M, (2005). Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev 2: CD004429.
26. Vlam L, Van der Pol WL, Cats EA, Straver DC, Piepers S, Franssen H, van den Berg LH, (2011). Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies. Nat Rev Neurol 8: 48-58.
27. Willison HJ, Yuki N, (2002). Peripheral neuropathies and anti-glycolipid antibodies. Brain 125: 2591-2625. (Pubitemid 35423511)
28. Wittstock M, Benecke R, Zettl UK, (2003). Therapy with intravenous immunoglobulins: complications and side-effects. Eur Neurol 50: 172-175. (Pubitemid 37256053)